Neurokinin-Targeted Therapies and Their Incorporation Into Clinical Guidelines
A panelist discusses how the potential of neurokinin-targeted therapies to provide targeted symptom relief with fewer side effects represents a significant advancement in menopause care while noting their likely incorporation into treatment guidelines as first-line options for moderate to severe vasomotor symptoms pending long-term safety data.
Video content above is prompted by the following:
- What excites you most about the potential of neurokinin-targeted therapies in redefining menopause care?
- How do you foresee fezolinetant or elinzanetant being incorporated into guidelines for vasomotor symptom (VMS) treatment?
Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease
December 12th 2024Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.
Read More
Evolving Role of Statins in Managing CV Risk in HIV | ID Week 2024
October 18th 2024Statins have had an evolving role in the management of cardiovascular risk in people living with HIV, explained Michelle Cespedes, M.D., M.S., professor of medicine, Icahn School of Medicine at Mount Sinai and Mount Sinai Health System.
Read More
